Table 2.
Effects of induced NCX1 transgene expression on levels of selected proteins
| WT | Non-Ind | Induced | |
|---|---|---|---|
| NCX1 | 28.4±0.8 (4) | 27.1±2.5 (5) | 54.2±3.7*(5) |
| SERCA2 | 89.2±1.8 | 85.3±2.2 | 81.4±2.4 |
| α1, Na+-K+-ATPase | 61.3±6.7 | 74.8±5.4 | 57.8±3.0 |
| α2, Na+-K+-ATPase | 42.8±2.7 | 49.9±3.0 | 49.7±0.8 |
| PLM, unphosphorylated | 16.8±2.5 | 13.9±3.8 | 11.0±1.4 |
| PLM, phosphorylated | 46.4±5.9 | 45.1±5.6 | 44.4±5.8 |
| Calsequestrin | 106.9±4.8 | 120.2±4.5 | 112.9±4.5 |
| RyR2 | 14.9±2.3 | 11.0±2.8 | 14.9±0.4 |
| PLBH | 43.9±8.8 | 56.4±11.9 | 40.4±4.6 |
| PLBL | 31.8±4.6 | 44.6±3.3 | 35.0±7.0 |
Values are means ± SE; numbers in parentheses are numbers of hearts used in crude membrane preparations. SERCA2, sarco(endo)plasmic reticulum Ca2+-ATPase; PLM, phospholemman; RyR2, cardiac ryanodine receptor; PLBH, high molecular weight phospholamban; PLBL, low molecular weight phospholamban.
*
P < 0.0005 compared with WT or Non-Ind. Since the π11-13 signal is 1.7× stronger for mouse than rat NCX1 (Fig. 2), the corrected NCX1 protein level is ∼2.54× in Induced when compared with WT or Non-Ind myocytes.